Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × decitabine and cedazuridine drug combination × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 12 Myeloid 7 Lymphoid 2 Breast 2 Thoracic 1 NET 1 Head & Neck 1 Genitourinary 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 8 lutetium Lu 177 dotatate 6 Magnetic Resonance Spectroscopy 6 Specimen Handling 3 Nivolumab 3 Fluorodeoxyglucose F18 3 pasireotide 2 olaparib 2 Positron Emission Tomography Computed Tomography 2 Ipilimumab 2 Ga(III)-DOTATOC 2 FAPI-46 2 (177)Lu-DOTA-EB-TATE 2 veliparib 1 toripalimab 1 tislelizumab 1 talazoparib 1 surufatinib 1 peposertib 1 pembrolizumab 1 gallium Ga 68 dotatate 1 fosbretabulin 1 fludarabine phosphate 1 exemestane 1 decitabine and cedazuridine drug combination 1 dactolisib 1 cabozantinib 1 amino-acid, glucose, and electrolyte solution 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05178693 2025-11-24

LANTana

Imperial College London

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡